HUP9702035A2 - Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek, valamint e vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek, valamint e vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP9702035A2
HUP9702035A2 HU9702035A HUP9702035A HUP9702035A2 HU P9702035 A2 HUP9702035 A2 HU P9702035A2 HU 9702035 A HU9702035 A HU 9702035A HU P9702035 A HUP9702035 A HU P9702035A HU P9702035 A2 HUP9702035 A2 HU P9702035A2
Authority
HU
Hungary
Prior art keywords
compounds
cell
general formula
vla
adhesion
Prior art date
Application number
HU9702035A
Other languages
English (en)
Inventor
Eckart Bartnik
Christoph Hüls
Jochen Knolle
Hans Ulrich Stilz
Volkmar Wehner
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of HU9702035D0 publication Critical patent/HU9702035D0/hu
Publication of HUP9702035A2 publication Critical patent/HUP9702035A2/hu
Publication of HUP9702035A3 publication Critical patent/HUP9702035A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány szerinti vegyületek (I) általánős képletébenW, Y, A, B, D és E jelentése egymástól függetlenül szerves csőpőrt,Zjelentése őxigén- vagy kénatőm vagy szerves csőpőrt,Rjelentése hidrőgénatőm vagy szerves csőpőrt,b, c, d és f értéke egymástól függetlenül 0 vagy 1, azzal amegkötéssel, hőgy egyidejűleg legalább egyikük értéke 0-tól eltérő, ése, g és h értéke egymástól függetlenül 0, 1, 2, 3, 4, 5 vagy 6.A találmány tárgykörébe tartőznak tővábbá (I) általánős képletűvegyületek és e vegyületeket tartalmazó gyógyászati készítményekalkalmazása őlyan betegségek kezelésére vagy megelőzésére, amelyeketleűkőciták nem kívánatős mértékű adhéziója és/vagy migrációja őkőzvagy azzal kapcsőlatősak, vagy amelyeknél a VLA-4-receptőrők ésligandűmaik kapcsőlatán alapűló sejt-sejt vagy sejt-mátrixkölcsönhatásők szerepet játszanak, így gyűlladásős főlyamatők, reűmásízületi gyűlladásők vagy allergiás megbetegedések esetén. A találmányvőnatkőzik tővábbá az (I) általánős képletű vegyületek alkalmazásárailyen betegségeknél használandó gyógyászati készítményekelőállítására.ŕ
HU9702035A 1996-11-15 1997-11-14 Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them HUP9702035A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19647380A DE19647380A1 (de) 1996-11-15 1996-11-15 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten

Publications (3)

Publication Number Publication Date
HU9702035D0 HU9702035D0 (en) 1998-01-28
HUP9702035A2 true HUP9702035A2 (hu) 1998-07-28
HUP9702035A3 HUP9702035A3 (en) 1998-12-28

Family

ID=7811830

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702035A HUP9702035A3 (en) 1996-11-15 1997-11-14 Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them

Country Status (30)

Country Link
US (1) US20040220148A1 (hu)
EP (1) EP0842943B1 (hu)
JP (1) JPH10147573A (hu)
KR (1) KR19980042457A (hu)
CN (1) CN1135236C (hu)
AR (1) AR010067A1 (hu)
AT (1) ATE233276T1 (hu)
AU (1) AU747789B2 (hu)
BR (1) BR9705727A (hu)
CA (1) CA2220784A1 (hu)
CZ (1) CZ293351B6 (hu)
DE (2) DE19647380A1 (hu)
DK (1) DK0842943T3 (hu)
ES (1) ES2190503T3 (hu)
HR (1) HRP970605B1 (hu)
HU (1) HUP9702035A3 (hu)
ID (1) ID19010A (hu)
IL (1) IL122188A0 (hu)
MX (1) MX9708782A (hu)
MY (1) MY119617A (hu)
NO (1) NO317241B1 (hu)
NZ (1) NZ329178A (hu)
PL (1) PL323128A1 (hu)
PT (1) PT842943E (hu)
RU (1) RU2229296C2 (hu)
SI (1) SI0842943T1 (hu)
SK (1) SK284377B6 (hu)
TR (1) TR199701354A2 (hu)
TW (1) TW496874B (hu)
ZA (1) ZA9710244B (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1056714B1 (en) 1998-02-26 2004-08-11 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
RU2255933C9 (ru) * 1999-05-07 2005-11-20 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ ПРОПИОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6630503B1 (en) 1999-08-13 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EE200200372A (et) 1999-12-28 2003-12-15 Pfizer Products Inc. VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviks
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
WO2001098268A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
EP1301488A1 (en) 2000-07-07 2003-04-16 Celltech R&D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
WO2003019136A2 (en) * 2001-08-06 2003-03-06 The Regents Of The University Of California Methods for inhibiting angiogenesis
UA82698C2 (uk) 2003-05-30 2008-05-12 Ранбакси Лабораториз Лимитед Заміщені похідні піролу та їх використання в якості інгібіторів hmg-co
JP2007509042A (ja) 2003-09-29 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 造血前駆細胞の接着、分化および遊走を変化させるための方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US8808698B2 (en) 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
WO2009126920A2 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
MD20140044A2 (ro) 2011-11-11 2014-08-31 Pfizer Inc. 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
KR20170132326A (ko) 2015-05-05 2017-12-01 화이자 인코포레이티드 2-티오피리미딘온
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
ATE212990T1 (de) * 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
PL323130A1 (en) * 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) * 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
TR199701354A3 (tr) 1998-06-22
US20040220148A1 (en) 2004-11-04
CN1135236C (zh) 2004-01-21
HRP970605A2 (en) 1998-08-31
CN1187490A (zh) 1998-07-15
MY119617A (en) 2005-06-30
PT842943E (pt) 2003-07-31
CZ359997A3 (cs) 1998-06-17
ID19010A (id) 1998-06-04
KR19980042457A (ko) 1998-08-17
MX9708782A (es) 1998-05-31
AU747789B2 (en) 2002-05-23
EP0842943B1 (de) 2003-02-26
NZ329178A (en) 2001-01-26
EP0842943A2 (de) 1998-05-20
NO317241B1 (no) 2004-09-27
RU2229296C2 (ru) 2004-05-27
CZ293351B6 (cs) 2004-04-14
DE59709383D1 (de) 2003-04-03
ZA9710244B (en) 1998-05-15
ES2190503T3 (es) 2003-08-01
AU4515997A (en) 1998-05-21
JPH10147573A (ja) 1998-06-02
SK284377B6 (sk) 2005-02-04
NO975244L (no) 1998-05-18
TW496874B (en) 2002-08-01
TR199701354A2 (xx) 1998-06-22
DK0842943T3 (da) 2003-06-02
HRP970605B1 (en) 2003-08-31
SK152697A3 (en) 1998-06-03
ATE233276T1 (de) 2003-03-15
HU9702035D0 (en) 1998-01-28
DE19647380A1 (de) 1998-05-20
NO975244D0 (no) 1997-11-14
PL323128A1 (en) 1998-05-25
AR010067A1 (es) 2000-05-17
BR9705727A (pt) 2000-03-21
HUP9702035A3 (en) 1998-12-28
SI0842943T1 (en) 2003-08-31
EP0842943A3 (de) 1999-02-24
CA2220784A1 (en) 1998-05-15
IL122188A0 (en) 1998-04-05

Similar Documents

Publication Publication Date Title
HUP9702035A2 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP9702036A1 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP9702034A2 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0102477A2 (hu) VLA-4 függő sejtadhézió nempeptid inhibitorainak felhasználása gyulladásos, autoimmun és légzési betegségek kezelésére és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0102475A2 (hu) Új acil-pszeudopeptidek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO942064L (no) yminhibitorer
EA200500875A1 (ru) Производные 3-аминопирролидина в качестве модуляторов рецепторов хемокинов
WO2004098518A3 (en) Pyrazole-amide compounds useful as kinase inhibitors
FR2528038B2 (fr) Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
HUP0401738A2 (hu) Prolin után hasító proteázok inhibitorai és ezeket tartalmazó gyógyszerkészítmények
TR199900920T2 (xx) Nafthiridin t�revleri.
HUP0003250A1 (hu) Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények
NO20043290D0 (no) Deazapuriner og anvendelse av slike
ES477653A1 (es) Un procedimiento para la preparacion de nuevos derivados de aminoazucares.
HUP0303107A2 (hu) Gyulladásos betegségek kezelésére alkalmazható vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0002050A2 (hu) Szubsztituált imidazolvegyületek, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0000762A2 (hu) 2-Amino-6-(2-szubsztituált-4-fenoxi)piridin-származékok, valamint a vegyületeket tartalmazó gyógyászati készítmények
NO944946D0 (no) Forgrenet-amino-substituerte tiazoler, fremgangsmåter for fremstilling av dem og farmasöytiske blandinger inneholdende dem
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
HUP0002442A2 (hu) Heterociklusos tio-észterek nitrogénen át kapcsolódó karbamid- és karbamátszármazékai, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
MX2007000061A (es) Mezclas fungicidas.
ES8203842A1 (es) Procedimiento para la obtencion de 4-aralquil-1,4-dihidro- pirdinas
ATE1143T1 (de) Prostan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutischen zusammensetzungen.
DE3370619D1 (de) Indole derivatives

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees